Publication: Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy
Issued Date
2011-04-01
Resource Type
ISSN
09675868
Other identifier(s)
2-s2.0-79952186468
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Neuroscience. Vol.18, No.4 (2011), 515-519
Suggested Citation
Nongnuch Sirachainan, Issarang Nuchprayoon, Pattra Thanarattanakorn, Samart Pakakasama, Apasri Lusawat, Anannit Visudibhan, Mantana Dhanachai, Noppadol Larbcharoensub, Jiraporn Amornfa, Kanchana Shotelersuk, Kamornwan Katanyuwong, Saipin Tangkaratt, Suradej Hongeng Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy. Journal of Clinical Neuroscience. Vol.18, No.4 (2011), 515-519. doi:10.1016/j.jocn.2010.08.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12582
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Post-surgical craniospinal irradiation (CSI; 30-36 Gy) plus local boost radiation therapy (RT; 54-56 Gy) is a standard treatment for children with medulloblastoma who are over 3 years old, resulting in a 5-year overall survival (OS) rate of 46% to 65% in average-risk patients and 50% in high-risk patients. The addition of chemotherapy has the benefit of reducing complications from radiation and improving the OS rate. Using this approach, the estimated 5-year OS rates for patients with average- and high-risk medulloblastomas treated with different protocols are 65% to 85% and 16% to 70%, respectively. In this study, we determined the outcome of patients with average- and high-risk medulloblastomas treated with reduced dosage CSI and chemotherapy with an oral etoposide-based regimen. The study included 49 patients, with a mean age of 7.7 ± 3.4 years. Twenty-six patients (53%) were classified as average-risk and 23 patients (47%) as high-risk. In the average-risk group, the 5-year progression free survival (PFS) rate was 62.9% ± 10% and the 5-year OS rate was 70.4% ± 9.5%. In the high-risk group the 5-year PFS rate was 48.9% ± 13% and the 5-year OS rate was 49.7% ± 13%. In the average-risk group, patients who received CSI of either 24 Gy (n = 20) or 36 Gy (n = 9) showed no difference in their 5-year PFS and OS rates. We found that patients who were ≤10 years old and patients who were female had a significantly better 5-year PFS rate. © 2010 Elsevier Ltd. All rights reserved.